Insider Selling: Natera Inc (NASDAQ:NTRA) CEO Sells 1,155 Shares of Stock

Natera Inc (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 1,155 shares of Natera stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $29.50, for a total transaction of $34,072.50. Following the completion of the transaction, the chief executive officer now directly owns 4,525 shares in the company, valued at $133,487.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

  • On Friday, August 9th, Steven Leonard Chapman sold 98,996 shares of Natera stock. The shares were sold at an average price of $33.00, for a total transaction of $3,266,868.00.
  • On Monday, June 24th, Steven Leonard Chapman sold 390 shares of Natera stock. The stock was sold at an average price of $25.19, for a total transaction of $9,824.10.

Shares of Natera stock traded up $0.55 during trading hours on Wednesday, hitting $30.55. 529,134 shares of the company were exchanged, compared to its average volume of 680,728. Natera Inc has a 1 year low of $11.08 and a 1 year high of $33.55. The company has a current ratio of 2.54, a quick ratio of 2.42 and a debt-to-equity ratio of 1.10. The business has a 50-day moving average of $29.82 and a 200-day moving average of $23.68. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -14.21 and a beta of 1.43.



Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Wednesday, August 7th. The medical research company reported ($0.48) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.57) by $0.09. Natera had a negative return on equity of 273.92% and a negative net margin of 46.78%. The firm had revenue of $74.36 million during the quarter, compared to the consensus estimate of $66.77 million. During the same period last year, the company earned ($0.62) earnings per share. The company’s revenue for the quarter was up 17.9% on a year-over-year basis. As a group, research analysts anticipate that Natera Inc will post -2.1 earnings per share for the current fiscal year.

Several brokerages have issued reports on NTRA. Craig Hallum raised their price objective on shares of Natera from $29.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. BidaskClub raised shares of Natera from a “hold” rating to a “buy” rating in a report on Friday, August 9th. Zacks Investment Research raised shares of Natera from a “sell” rating to a “hold” rating in a report on Friday, August 9th. Canaccord Genuity increased their target price on shares of Natera from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. Finally, Piper Jaffray Companies reissued a “buy” rating on shares of Natera in a report on Thursday, August 22nd. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Natera has an average rating of “Buy” and an average price target of $32.57.

A number of institutional investors have recently made changes to their positions in NTRA. Focused Wealth Management Inc acquired a new stake in shares of Natera in the 2nd quarter worth $83,000. US Bancorp DE boosted its holdings in shares of Natera by 575.2% in the second quarter. US Bancorp DE now owns 3,099 shares of the medical research company’s stock valued at $86,000 after acquiring an additional 2,640 shares in the last quarter. Bank of Montreal Can purchased a new stake in shares of Natera in the second quarter valued at about $129,000. BNP Paribas Arbitrage SA increased its stake in shares of Natera by 827.1% during the first quarter. BNP Paribas Arbitrage SA now owns 7,899 shares of the medical research company’s stock worth $163,000 after acquiring an additional 7,047 shares during the period. Finally, United Services Automobile Association acquired a new position in shares of Natera during the second quarter worth about $242,000. Institutional investors own 94.95% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: NASDAQ

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.